Tango Therapeutics’ Vopimetostat plus Daraxonrasib achieved a 92% objective response rate and 90% six-month progression-free survival in pancreatic cancer, with no grade 4–5 adverse events. Wolfe Research raised global peak sales to $2.6B from $1.9B and set a $35 price target, while Mizuho lifted its target to $36.
Data from the Phase 1/2 study show that combining Vopimetostat with Daraxonrasib achieved a 92% objective response rate in advanced pancreatic cancer patients, with 90% progression-free survival at six months. No grade 4 or 5 adverse events were reported and no patients discontinued treatment due to side effects.
Following the trial results, Wolfe Research upgraded Tango to Outperform, raised the global peak sales estimate for Vopimetostat from $1.9B to $2.6B and set a $35 price target. Mizuho increased its price target to $36 and raised the probability of regulatory success to 75% from 30–40%.
Tango plans to advance the Vopimetostat and Daraxonrasib combination into Phase 3 testing as a potential chemotherapy-free treatment for pancreatic cancer, aiming to confirm efficacy and safety in a larger patient population.
